ATE175210T1 - Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) - Google Patents

Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Info

Publication number
ATE175210T1
ATE175210T1 AT91115080T AT91115080T ATE175210T1 AT E175210 T1 ATE175210 T1 AT E175210T1 AT 91115080 T AT91115080 T AT 91115080T AT 91115080 T AT91115080 T AT 91115080T AT E175210 T1 ATE175210 T1 AT E175210T1
Authority
AT
Austria
Prior art keywords
chicken
cnp
biologically active
derived peptide
new biologically
Prior art date
Application number
AT91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Suntory Ltd
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd, Hisayuki Matsuo filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE175210T1 publication Critical patent/ATE175210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91115080T 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp) ATE175210T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
ATE175210T1 true ATE175210T1 (de) 1999-01-15

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91115080T ATE175210T1 (de) 1990-09-07 1991-09-06 Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)

Country Status (8)

Country Link
US (1) US5338830A (de)
EP (1) EP0475291B1 (de)
JP (1) JP2977158B2 (de)
AT (1) ATE175210T1 (de)
DE (1) DE69130696T2 (de)
DK (1) DK0475291T3 (de)
ES (1) ES2127190T3 (de)
GR (1) GR3029628T3 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
EP3446711A1 (de) 2004-03-31 2019-02-27 Kazuwa Nakao Zusammensetzung zur erhöhung der körpergrösse
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US20190119325A1 (en) * 2015-07-31 2019-04-25 Igisu Co., Ltd. Cnp cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
EP3426286A4 (de) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei kindern
EP3436020A4 (de) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DE69130696D1 (de) 1999-02-11
DE69130696T2 (de) 1999-06-10
ES2127190T3 (es) 1999-04-16
GR3029628T3 (en) 1999-06-30
EP0475291A1 (de) 1992-03-18
JP2977158B2 (ja) 1999-11-10
EP0475291B1 (de) 1998-12-30
JPH04120094A (ja) 1992-04-21
DK0475291T3 (da) 1999-08-30
US5338830A (en) 1994-08-16

Similar Documents

Publication Publication Date Title
ATE175210T1 (de) Ein neues, biologisch aktives vom huhn stammendes peptid (huhn-cnp)
ATE175211T1 (de) Neues, biologisch aktives, vom frosch stammendes peptid (frosch-cnp)
DE68921850T2 (de) Reinigung von durch Verwendung von Doppelmetallcyanidkomplexkatalysatoren hergestellten Polyolen.
DE69013313T2 (de) Mehrstufenverfahren zur Herstellung von Hexafluorpropylen.
DE59304248D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
DE69300497D1 (de) Silberkatalysator zur Herstellung von Äthylenoxid.
ATE39249T1 (de) Verfahren zur herstellung von polyisocyanatopolyisocyanuraten durch katalytische cyclotrimerisierung von polyisocyanaten.
DE69008326T2 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
NO895028L (no) Ny chimerisk transformerende vekstfaktor-beta.
DE69010171D1 (de) Mehrstufenverfahren zur Herstellung von Hexafluoropropylen.
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
DE59102062D1 (de) Verfahren zur biologischen Reinigung von Abluftströmen.
DE59308152D1 (de) Mehrstufenprozess zur Herstellung von thermoplastisch verarbeitbaren Polyurethan-Elastomeren
DE3873342T3 (de) Nicht-zylindrischer reaktor zur herstellung von furnace-russ.
ATE305044T1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
ATE221121T1 (de) Verwendung einer dna sequenz, kodierende für ein protein mit der fäligkeit oxalsäure abzubauen, zur genselektion
DE3689008D1 (de) Verfahren zur Herstellung und Reinigung von alpha-Interferon.
DE69116803T2 (de) Peroxidase-Gen von mikrobischem Ursprung
DE69002017T2 (de) Katalytisches Verfahren zur Herstellung von Oximen.
DE3750624T2 (de) Durchlaufreaktor für Peptidsequenatoren.
DE69105885T2 (de) Katalytisches Verfahren zur Herstellung von sec-Butylbenzol.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.
ATE53380T1 (de) Katalytisches verfahren zur herstellung von oximen.
DE3876788T2 (de) Erzeugnis, enthaltend als wirkstoffe: a) ein peptid mit einer wirkung von der art des gamma-hu-interferons b) hydroxyharnstoff.
DE69206116D1 (de) Verfahren zur Reinigung von 1,1-Dichlor-1-Fluorethan.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee